Introductory Offer on New Products - Antibodies for Exosomal Markers CD9, CD81. Free Shipping in Taiwan.

UNMET NEEDS

2019年時,將會有580萬的美國人罹患阿茲海默症,且有高達3500萬的世界人口會罹患阿茲海默症。此圖顯示在2050年時,預估會有1400萬的美國人罹患阿茲海默症。 阿茲海默症協會2018年的研究報告指出,2000年至2015年間,死因為阿茲海默的人數增加超過兩倍,上升了123%。反觀,與美國的主要死因—心臟疾病,死亡人數下降11%形成強烈的對比。

1
million
Americans living with Alzheimer’s in 2019
1
million
Americans estimated to have Alzheimer’s by 2050
1
million
People living with Alzheimer’s worldwide in 2019
In 2019, 5.8 million Americans are living with AD, and 35 million worldwide. This figure is estimated to reach 14 million Americans by 2050. The 2018 report from Alzheimer’s Association reported between 2000 and 2015, deaths from AD have more than doubled, rising 123% which is in starch contrast to a decline of 11% mortality from heart disease, the leading cause of death in US.

Market Opportunity

The US healthcare cost of caring for Alzheimer's Disease, and other dementias is $206 billion in 2020.
By the time we reach 2050, it is projected to cost $777 billion.

Most of these patients’ amyloid-β protein level are unknown to their attending physicians since PET-scan costs $3000 to $4000 (without imbursement from CMS) and invasive spinal tap for CSF has low patients’ acceptance. Knowledge of amyloid-β protein level is clinically actionable. JAMA (April 2019) published a CMS-sponsored clinical trial where 11,409 patients with dementia completed PET-scan for amyloid-β. Results showed attending physicians changed management of 61% (6,959) of patients with known amyloid-β information.

In addition to sales to diagnostic companies or hospitals, another opportunity is companion diagnostics for pharmas in characterizing amyloid-β levels of subjects prior to enrollment for Alzheimer's Disease-related clinical trials. Recent interaction with IQVIA, the largest CRO worldwide, confirmed that this is an extremely urgent need for pharmas.